Pancreatic Cancer Research

ResearcherIRCCS Humanitas Research HospitalActive in the last 2 years

Silvia Bozzarelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8118-7342; OpenAlex author ID A5077674399. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 7 papers · 2024: 1 paper · 2025: 3 papers · 2026: 3 papers

Papers 19

  1. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  2. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  3. Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive T… Co-author DOI 10.1158/2326-6066.cir-25-1602↗
  4. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  5. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
  6. Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional … Co-author DOI 10.1016/j.esmoop.2024.104001↗
  7. Depicting the cellular complexity of pancreatic adenocarcinoma by Imaging Mass Cytometry: focus on cancer-associated fibroblasts. Co-author DOI 10.3389/fimmu.2024.1472433↗
  8. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  9. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis? Co-author DOI 10.1007/s13304-023-01628-y↗
  10. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  11. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  12. Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol30040282↗
  13. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. Last author DOI 10.3390/curroncol30040293↗
  14. Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity … Co-author DOI 10.3390/curroncol30070513↗
  15. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival. Co-author DOI 10.1016/j.dld.2021.06.006↗
  16. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2022.05.006↗
  17. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  18. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. Co-author DOI 10.1259/bjr.20190627↗
  19. Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Co-author DOI 10.2217/fon-2019-0480↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Zerbi · 7 shared papers, 2022–2026 · strength 1.21
  2. Marina Macchini · 7 shared papers, 2021–2026 · strength 1.13
  3. Giulia Orsi · 7 shared papers, 2021–2026 · strength 1.13
  4. Michèle Milella · 7 shared papers, 2021–2026 · strength 1.13
  5. Michele Reni · 7 shared papers, 2021–2026 · strength 1.13
  6. Ilario Giovanni Rapposelli · 7 shared papers, 2021–2026 · strength 1.10
  7. Letizia Procaccio · 6 shared papers, 2023–2026 · strength 1.04
  8. Giovanni Luigi Capretti · 5 shared papers, 2022–2026 · strength 0.88
  9. Elisa Giommoni · 6 shared papers, 2021–2025 · strength 0.86
  10. Gennaro Nappo · 5 shared papers, 2022–2024 · strength 0.85
  11. Mario Scartozzi · 5 shared papers, 2021–2026 · strength 0.80
  12. Mariacristina Di Marco · 5 shared papers, 2021–2026 · strength 0.80
  13. Monica Niger · 5 shared papers, 2021–2025 · strength 0.67
  14. Greta Donisi · 3 shared papers, 2023–2026 · strength 0.59
  15. Lisa Salvatore · 4 shared papers, 2023–2025 · strength 0.58
  16. Francesca Bergamo · 3 shared papers, 2025–2026 · strength 0.54
  17. Ingrid Garajová · 4 shared papers, 2021–2025 · strength 0.53
  18. Guido Giordano · 4 shared papers, 2021–2025 · strength 0.51
  19. Giampaolo Tortora · 4 shared papers, 2021–2025 · strength 0.51
  20. Stefano Cascinu · 4 shared papers, 2021–2025 · strength 0.51
  21. Sara Lonardi · 3 shared papers, 2023–2026 · strength 0.50
  22. Francesca Gavazzi · 3 shared papers, 2022–2023 · strength 0.47
  23. Silvia Carrara · 3 shared papers, 2022–2023 · strength 0.44
  24. Giuseppe Malleo · 2 shared papers, 2026 · strength 0.43
  25. Catia Carconi · 2 shared papers, 2026 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.